Trulieve’s Dual-Track Bet: A New York Listing, a Delaware Home, and Washington’s Slow-Moving Cannabis Clock

When Trulieve Cannabis Corp. rang the closing bell at the New York Stock Exchange in August, the ceremony capped a corporate transformation that had been months in the making. The company had already begun trading on the NYSE on June 10 as the first US cannabis operator to secure a listing on that exchange, but the August 18 celebration — complete with the traditional bell-ringing — underscored just how much structural work had been required to get there.

The path to that milestone ran through a change of corporate domicile. Shareholders approved the move on August 5, a Canadian court issued its final order on August 10, and the company completed its relocation from British Columbia to Delaware on August 11. In the process, investors swapped their existing shares on a one-for-one basis for new Class A and Class B stock under Delaware law. The ticker remained TRLV.

Two Regulatory Fronts, One Investment Thesis

The listing ceremony, however, was only half the story. Trulieve is simultaneously navigating two distinct layers of federal cannabis regulation, each with different implications for the business.

The narrower — and already settled — matter concerns medical cannabis. Since April 28, a DEA ruling has placed cannabis in FDA-approved drugs and state-licensed medical marijuana into Schedule III, the far less restrictive drug category. Trulieve’s consolidated operations, following its restructuring, consist precisely of such state-licensed medical businesses. That means the company already benefits from the more favorable classification today. All 207 of its medical dispensaries are now registered with the DEA, with inspections completed in Florida, Pennsylvania, and West Virginia.

The broader fight involves recreational cannabis. In a filing dated August 17, the DEA itself urged the presiding judge to move cannabis from Schedule I — the most restrictive category — to Schedule III. The agency cited evidence gathered during a nearly three-week hearing that ran from June 29 to July 15. Chief Administrative Law Judge Derek Julius received the filing alongside a series of opposing briefs from groups including Smart Approaches to Marijuana, the states of Idaho, Indiana, and Nebraska, the Tennessee Bureau of Investigation, and the National Drug and Alcohol Screening Association.

With the written arguments now submitted, the ball sits with Judge Julius, who must issue a recommendation before the DEA’s administration makes a final call. No firm timeline binds that process, and market observers caution against betting on a swift resolution.

The Operational Picture: Momentum Meets Friction

The regulatory developments have given the stock a visible lift. Over the past month, shares have gained roughly 29 percent, with investors seemingly positioning for a favorable outcome in the ongoing proceeding.

Yet the operating numbers tell a more complicated story. Second-quarter revenue came in at $271 million, down 10 percent year over year, with a gross margin of 60 percent. The company posted a GAAP net loss of $406 million, driven largely by a one-time, non-cash charge of $407 million tied to the deconsolidation of its Harvest recreational-market activities — a step required for the NYSE listing. Adjusted EBITDA reached $98 million, translating to a 36 percent margin.

Should investors sell immediately? Or is it worth buying Trulieve?

The balance sheet offers some ballast. Trulieve reported operating cash flow of $109 million for the first half, free cash flow of $74 million, and a cash position of $325 million as of June 30. Still, management trimmed its full-year operating cash flow guidance to at least $225 million, down from a prior target of $250 million.

Analysts have responded with a mix of caution and conviction. Alliance Global Partners reaffirmed its buy rating on August 22 with a price target of C$27, pointing to Trulieve’s unique positioning in pure medical markets and its expansion potential in Texas and Georgia. Cantor Fitzgerald, following the quarterly results, maintained its overweight rating with a $15 price target. An automated valuation model, meanwhile, flags strong price momentum but weak growth and valuation metrics — a reminder that the operational story has yet to catch up with the regulatory tailwind.

Regional Expansion and Insider Activity

Beyond the federal picture, Trulieve is pressing ahead with state-level growth. In Georgia, the company has launched new product lines under the “Modern Flower” and “Roll One” brands following the expansion of the state program under SB 220. In Texas, Trulieve says its production capacity for all eleven public health regions is ready for final acceptance testing.

The insider-trading tape, however, shows some selling. CEO Kim Rivers disposed of roughly 136,800 shares in late June at an average price of $8.76, for a total of about $1.2 million, under a pre-arranged trading plan. Over the preceding 90 days, insider sales totaled approximately 1.7 million shares.

What a Schedule III Win Would — and Wouldn’t — Change

Should the broader recreational cannabis proceeding succeed, the implications would ripple across the industry. The elimination of Section 280E of the US tax code — which currently bars cannabis companies from deducting ordinary business expenses — would be the most consequential outcome, alongside improved research access and generally lighter federal oversight.

But Schedule III would not amount to full legalization. It would not legalize state markets, nor would it fully shield licensed operators from federal prosecution. That distinction tempers expectations of a swift, outsized windfall.

For now, investors are left weighing the potential of meaningful tax relief against the uncertainty of when — or whether — the DEA will deliver a final decision. With the evidentiary record closed and briefs submitted, the coming weeks are likely to be shaped by regulatory news rather than operational catalysts. Trulieve’s next scheduled reporting date is November 7, when third-quarter results will show whether the company’s regulatory progress is beginning to translate into the bottom line.